由于靶向CD19的CAR-T细胞疗法可以清除整个B细胞群体,因此它具有治疗多种自身免疫性疾病的潜力。根据ClinicalTrials.gov上的信息,截至2023年5月31日,有超过20项临床试验正在进行中,检验CAR-T疗法用于治疗自身免疫性疾病的潜力。 利用调节性T细胞建立免疫耐受性 清除致病B细胞的策略之外,利用调节性T细胞(Tregs)抑制自身免...
参考文献: 1.Engineered TCR-T CellI mmunotherapy in Anticancer Precision Medicine: Pros and Cons. Front Immunol. 2021;12: 658753. 2. Evolution of CD8+ T Cell Receptor(TCR) Engineered Therapies for the Treatment of Cancer. Cells. 2021 Sep;10(9): 2379....
[5]FDA probes CAR-T therapies' 'serious risk' of secondary cancer [6]Bonaldo G, Montanaro N, AlbertoVaccheri, Motola D. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice. Eur J Clin Pharmacol. 2021 Aug;77(8):1225-1234. doi: 10.1007/s00228...
2023年10月12日,科济药业宣布其自主研发的靶向GPC3的CAR-T细胞治疗晚期肝细胞癌(HCC)的两例患者的临床疗效。该临床试验结果刊登在《Cancer Communications》上,2例晚期肝细胞癌患者在入组时合并下腔静脉癌栓,其中1例伴有腹膜后淋巴结转移,预后治疗结局不理想。 ▲截自《Cancer Communications》 在临床试验中,一名患者...
[8] Ping, Yu, Chaojun Liu, and Yi Zhang. "T-cell receptor-engineered T cells for cancer treatment: current status and future directions." Protein & cell (2017): 1-13. [9] Srivastava, Shivani, and Stanley R. Riddell. "Engineering CAR-T cells: Design concepts." Trends in immunology ...
1.Engineered TCR-T CellI mmunotherapy in Anticancer Precision Medicine: Pros and Cons. Front Immunol. 2021;12: 658753. 2. Evolution of CD8+ T Cell Receptor(TCR) Engineered Therapies for the Treatment of Cancer. Cells. 2021 Sep;10(9): 2379....
NK-92 cells labeled with Fe3O4-PEG-CD56/Avastin@Ce6 nanoprobes for the targeted treatment and noninvasive therapeutic evaluation of breast cancer Jingge Lian Meng Li Kangan Li Journal of Nanobiotechnology(2024) An artificial metabzyme for tumour-cell-specific metabolic therapy ...
早在20世纪70年代,有研究表明只有一部分白血病细胞能够在体外增殖[10-12],随着更多的体内研究和体外研究的开展,逐渐发现在整个白血病细胞群体中,有一些罕见的细胞具有自我更新的潜力,从而驱动白血病克隆的扩展,因此提出白血病干细胞(leukemia stem cells,...
[11] Chen C, Li K, Jiang H, et al. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma[J]. Cancer immunology, immunotherapy: CII, 2017, 66(4): 475-489....
7, Changsong Qi, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nature Medicine, 2022. https://doi.org/10.1038/s41591-022-01800-8 8, Guocheng Zhong, et al. Complete remission of advanced pancreatic cancer induced by claudin18.2-...